Background and Purpose: Cognitive impairment (CI) is frequent after stroke, but data from population-based stroke cohorts on the natural course of CI are limited. The purpose of this study was to determine changes in cognitive status over 3 years after stroke. Methods: Data were collected from the Erlangen Stroke Project, an ongoing population-based stroke registry. The Mini-Mental State Examination (MMSE) for assessing global cognitive function was used; CI was defined as an MMSE score <24. Results: From February 1998 to January 2006, 630 patients with first-ever stroke were included. Prevalence rates of CI at 3 months, 1 and 3 years were 15, 13, and 12%. In multivariable analysis, stroke severity, i.e. Barthel index (p < 0.001), age (OR = 1.03; 95% CI = 1.00–1.05) and diabetes mellitus (OR = 2.03; 95% CI = 1.13–3.67) were associated with CI at 3 months. Recovery rate from CI at 3 months after stroke was found to be 31% over the following 3 years. Intact cognitive function rate was 71% over 3 years and inversely associated with age (OR = 0.96; 95% CI = 0.96–0.94) and stroke severity (p < 0.001). Conclusion: CI is frequent among stroke survivors and associated with age, stroke severity, and diabetes mellitus, but recovery occurs in approximately one third of the patients over the course of 3 years. Factors affecting intact cognitive function over time are increasing age and stroke severity.

Keywords:
Cognitive impairment, First-ever stroke, Population-based registry
1.
Oksala NKJ, Jokinen H, Melkas S, Oksala A, Pohjasvaara T, Hietanen M, Vataja R, Kaste M, Karhunen PJ, Erkinjuntti T: Cognitive impairment predicts poststroke death in long-term follow-up. J Neurol Neurosurg Psychiatry 2009;80:1230–1235.
2.
Pasquini M, Leys D, Rousseaux M, Pasquier F, Henon H: Influence of cognitive impairment on the institutionalisation rate 3 years after a stroke. J Neurol Neurosurg Psychiatry 2007;78:56–59.
3.
Appelros P: Characteristics of Mini-Mental State Examination 1 year after stroke. Acta Neurol Scand 2005;112:88–92.
4.
Patel MD, Coshall C, Rudd AG, Wolfe CDA: Cognitive impairment after stroke: clinical determinants and its associations with long-term stroke outcomes. J Am Geriatr Soc 2002;50:700–706.
5.
Ebrahim S, Nouri F, Barer D: Cognitive impairment after stroke. Age Ageing 1985;14:345–348.
6.
House A, Dennis M, Warlow C, Hawton K, Molyneux A: The relationship between intellectual impairment and mood disorder in the first year after stroke. Psychol Med 1990;20:805–814.
7.
Tatemichi TK, Desmond DW, Stern Y, Paik M, Sano M, Bagiella E: Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. J Neurol Neurosurg Psychiatry 1994;57:202–207.
8.
Pendlebury ST, Rothwell PM: Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009;8:1006–1018.
9.
Rasquin SM, Lodder J, Verhey FR: The effect of different diagnostic criteria on the prevalence and incidence of post-stroke dementia. Neuroepidemiology 2005;24:189–195.
10.
Tatemichi TK, Desmond DW, Paik M, Figueroa M, Gropen TI, Stern Y, Sano M, Remien R, Williams JB, Mohr JP, et al: Clinical determinants of dementia related to stroke. Ann Neurol 1993;33:568–575.
11.
Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F: Poststroke dementia. Lancet Neurol 2005;4:752–759.
12.
Patel M, Coshall C, Rudd AG, Wolfe CDA: Natural history of cognitive impairment after stroke and factors associated with its recovery. Clin Rehabil 2003;17:158–166.
13.
del Ser T, Barba R, Morin MM, Domingo J, Cemillan C, Pondal M, Vivancos J: Evolution of cognitive impairment after stroke and risk factors for delayed progression. Stroke 2005;36:2670–2675.
14.
Hochstenbach JB, den Otter R, Mulder TW: Cognitive recovery after stroke: a 2-year follow-up. Arch Phys Med Rehabil 2003;84:1499–1504.
15.
Heuschmann PU, Neureiter D, Gesslein M, Craiovan B, Maass M, Faller G, Beck G, Neundoerfer B, Kolominsky-Rabas PL: Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: results from a population-based case-control study. Stroke 2001;32:2253–2258.
16.
Kolominsky-Rabas PL, Heuschmann PU, Marschall D, Emmert M, Baltzer N, Neundörfer B, Schöffski O, Krobot KJ: Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006;37:1179–1183.
17.
Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann KG, von Stockert TR: A prospective community-based study of stroke in Germany – The Erlangen Stroke Project (ESPRO): incidence and case fatality at 1, 3, and 12 months. Stroke 1998;29:2501–2506.
18.
Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU: Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735–2740.
19.
Hatano S: Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976;54:541–553.
20.
Mok VCT, Wong A, Lam WWM, Fan YH, Tang WK, Kwok T, Hui ACF, Wong KS: Cognitive impairment and functional outcome after stroke associated with small vessel disease. J Neurol Neurosurg Psychiatry 2004;75:560–566.
21.
Tombaugh TN, McIntyre NJ: The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc 1992;40:922–935.
22.
Wade DT, Hewer RL: Functional abilities after stroke: measurement, natural history and prognosis. J Neurol Neurosurg Psychiatry 1987;50:177–182.
23.
Gorelick PB: Status of risk factors for dementia associated with stroke. Stroke 1997;28:459–463.
24.
Tatemichi TK, Desmond DW, Mayeux R, Paik M, Stern Y, Sano M, Remien RH, Williams JB, Mohr JP, Hauser WA, et al: Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992;42:1185–1193.
25.
Pendlebury ST: Stroke-related dementia: rates, risk factors and implications for future research. Maturitas 2009;64:165–171.
26.
Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M: Clinical determinants of poststroke dementia. Stroke 1998;29:75–81.
27.
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P: Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006;5:64–74.
28.
Hobson P, Meara J: Cognitive function and mortality in a community-based elderly cohort of first-ever stroke survivors and control subjects. J Stroke Cerebrovasc Dis 2010;19:382–387.
29.
Tham W, Auchus AP, Thong M, Goh ML, Chang HM, Wong MC, Chen CP: Progression of cognitive impairment after stroke: one year results from a longitudinal study of Singaporean stroke patients. J Neurol Sci 2002;203–204:49–52.
30.
Desmond DW, Moroney JT, Sano M, Stern Y: Recovery of cognitive function after stroke. Stroke 1996;27:1798–1803.
31.
Bour A, Rasquin S, Boreas A, Limburg M, Verhey F: How predictive is the MMSE for cognitive performance after stroke? J Neurol 2010;257:630–637.
32.
Dick JP, Guiloff RJ, Stewart A, Blackstock J, Bielawska C, Paul EA, Marsden CD: Mini-mental state examination in neurological patients. J Neurol Neurosurg Psychiatry 1984;47:496–499.
33.
Fure B, Bruun Wyller T, Engedal K, Thommessen B: Cognitive impairments in acute lacunar stroke. Acta Neurol Scand 2006;114:17–22.
34.
Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, Pondal M, Vivancos J, Del Ser T: Poststroke dementia: clinical features and risk factors. Stroke 2000;31:1494–1501.
35.
Tatemichi TK, Foulkes MA, Mohr JP, Hewitt JR, Hier DB, Price TR, Wolf PA: Dementia in stroke survivors in the stroke data bank cohort. Prevalence, incidence, risk factors, and computed tomographic findings. Stroke 1990;21:858–866.
36.
Kasner SE: Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603–612.
37.
Kelly-Hayes M, Robertson JT, Broderick JP, Duncan PW, Hershey LA, Roth EJ, Thies WH, Trombly CA: The American Heart Association stroke outcome classification. Stroke 1998;29:1274–1280.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.